By: Dr Zaid Matti
Musculoskeletal Medicine Specialist
An Emerging Regenerative Option for Nerve Pain and Sensory Dysfunction
Neuropathic pain is one of the most disabling consequences of diabetes and other nerve injuries. Patients often describe burning, tingling, electric-shock sensations, numbness, or a feeling of “walking on cotton” in the feet and legs. When this involves the feet, we call it diabetic foot neuropathy – a major contributor to falls, ulcers, infections and, in severe cases, amputation.
Conventional treatments (such as pregabalin, gabapentin, duloxetine and tricyclic antidepressants) act mainly by dampening pain signals in the nervous system. They can reduce symptoms, but they do not repair damaged nerves, improve microcirculation, or meaningfully change the underlying biology of neuropathy. Many patients remain symptomatic despite maximal medical therapy, or they experience limiting side-effects.
In regenerative medicine, we are increasingly interested in therapies that aim to support tissue repair and nerve regeneration rather than simply masking symptoms. One of the most promising tools in this space is platelet-rich plasma (PRP).
This article summarises:
- what PRP is and how it works on nerves
- the broader evidence for PRP in peripheral neuropathies
- the specific data for diabetic peripheral neuropathy (DPN)
- how this translates to diabetic foot neuropathy in clinical practice
- where PRP realistically sits today: promising, but still emerging
What Is PRP?
PRP is prepared from a small sample of your own blood. The blood is spun in a centrifuge to concentrate platelets and growth factors into a small volume of plasma. This plasma contains high levels of:
- Platelet-derived growth factor (PDGF)
- Vascular endothelial growth factor (VEGF)
- Nerve growth factor (NGF)
- Insulin-like growth factor-1 (IGF-1)
- Transforming growth factor-β (TGF-β)
- Many other cytokines and bioactive peptides
Platelets are not just “clotting cells”; they are biological signalling packages. When activated at an injury site they release growth factors that:
- reduce local inflammation
- promote micro-vascular repair
- stimulate supporting cells such as Schwann cells
- encourage axonal regrowth and remyelination
- improve the metabolic environment around damaged nerves
Because PRP is autologous (from your own blood), it is biologically compatible and carries a very low risk of allergic reaction or systemic side-effects.
Why Might PRP Help Neuropathy?
Peripheral neuropathy—whether due to diabetes, compression, trauma or surgery—usually involves a combination of:
- chronic low-grade inflammation
- impaired blood flow to the nerve
- oxidative stress and mitochondrial dysfunction
- loss of small nerve fibres
- structural damage (axonal degeneration and demyelination)
Pre-clinical research shows that PRP can positively influence all of these domains:
- Animal models of peripheral nerve injury demonstrate that PRP improves axonal regeneration, myelin thickness and functional recovery when applied around or within damaged nerves.
- Recent experimental work in rat sciatic nerve crush and neuropathic pain models shows that PRP or PRP gel can reduce TNF-α and IL-6 expression and alleviate neuropathic pain behaviours, supporting a direct anti-inflammatory, neuroprotective effect.
- Reviews of peripheral nerve regeneration consistently conclude that PRP creates a more favourable micro-environment for nerve healing, improving both structural and electrophysiological outcomes.
This biological rationale explains why PRP has moved from musculoskeletal applications (tendons, ligaments, joints) into nerve-focused indications, particularly entrapment neuropathies and diabetic neuropathy.
Evidence for PRP in Peripheral Neuropathies (Beyond Diabetes)
Before discussing diabetes specifically, it is helpful to look at the broader experience of PRP in other peripheral neuropathies, where the literature is more mature.
Carpal Tunnel Syndrome (Median Nerve Entrapment)
Several randomised controlled trials (RCTs) and systematic reviews have evaluated PRP for carpal tunnel syndrome (CTS):
- A prospective RCT from Wu et al. compared PRP injection with saline in mild-to-moderate CTS and found significant improvements in pain scores, function (Boston CTS Questionnaire) and median nerve cross-sectional area at 6 months in the PRP group.
- Chen et al. reported that PRP provided sustained symptom relief and functional improvement at one-year follow-up, suggesting more than a short-term placebo effect.
- Eltabl et al. compared ultrasound-guided PRP injection with both surgical decompression and conservative management, finding that PRP was comparable to surgery for pain and function in mild-to-moderate CTS, with lower procedural morbidity.
- A 2022 meta-analysis and a 2025 systematic review concluded that PRP is a safe and effective option for CTS, improving pain and patient-reported outcomes, with some evidence of improved nerve-conduction parameters.
Other Peripheral Neuropathies
A 2025 systematic review by Kennedy and colleagues examined PRP across multiple peripheral neuropathies—including CTS, ulnar neuropathy, common peroneal neuropathy and post-surgical nerve injuries. Overall, PRP:
- reduced neuropathic pain
- improved function and disability scores
- showed a favourable safety profile, with no serious PRP-related complications reported across the included studies.
Anitua et al. (2024) performed a systematic review of platelet derivatives in neuropathic pain more broadly (not limited to diabetes). Across seven randomised studies involving 429 patients, platelet-based treatments produced significant pain reductions compared with placebo, standard care or alternative interventions.
Taken together, these data indicate that PRP is not merely a niche idea; it has repeatedly shown analgesic and functional benefits in human peripheral neuropathy, particularly entrapment syndromes, with biological plausibility and supportive animal data.
PRP in Diabetic Peripheral Neuropathy (DPN)
In diabetic neuropathy, nerves are not just compressed—they are metabolically and structurally compromised by chronic hyperglycaemia, advanced glycation end-products, microvascular damage and oxidative stress. This is more complex than a simple mechanical entrapment.
Nevertheless, a growing body of clinical work suggests that PRP can meaningfully improve symptoms and nerve function in DPN.
1. Perineural PRP for Painful Diabetic Neuropathy – Hassanien et al.
Hassanien and colleagues conducted a randomised, controlled trial comparing perineural PRP injections with standard medical therapy in patients with painful diabetic neuropathy.
- Patients received ultrasound-guided injections of PRP around affected lower-limb nerves.
- Compared with controls, the PRP group demonstrated:
- significant reductions in pain and numbness (VAS scores) at 1, 3 and 6 months
- improved modified Toronto Clinical Neuropathy Score (mTCNS) at all follow-up points
- better sensory outcomes and nerve-conduction parameters
Conclusion: Perineural PRP was effective in reducing neuropathic pain and numbness and enhancing peripheral nerve function in DPN.
2. PRP vs Pregabalin – Anwar et al.
Anwar et al. performed a randomised controlled clinical trial comparing PRP injections to pregabalin in painful diabetic polyneuropathy.
- PRP was injected at acupuncture-related points along the lower limbs.
- Pain scores improved substantially in both groups, but the PRP group showed greater and more sustained reductions in pain intensity.
- Patients receiving PRP avoided the systemic side-effects commonly encountered with pregabalin (sedation, dizziness, weight gain).
Conclusion: PRP is at least as effective as pregabalin for pain relief in DPN, with a more favourable side-effect profile.
3. Randomised Case-Control Study – Elsayed et al.
Elsayed and colleagues (2025) undertook a randomised case-control study examining PRP therapy in patients with painful DPN.
- PRP therapy significantly alleviated neuropathic pain symptoms.
- Nerve-conduction studies showed improved sensory and motor parameters compared with baseline and with control patients receiving conventional therapy alone.
Conclusion: PRP may function as an effective adjunct treatment for DPN, improving both clinical symptoms and objective nerve function.
4. Ongoing and Related Work
Clinical trial registries now include dedicated studies of perineural PRP for DPN, reflecting growing academic and clinical interest in this approach.
Collectively, these studies show a consistent pattern:
- Meaningful pain reduction
- Improvement in numbness and sensory loss
- Better clinical neuropathy scores
- In several trials, improved nerve-conduction parameters
- Good short-term safety, with no major PRP-related adverse events reported
Diabetic Foot Neuropathy: Why Regeneration Matters
In everyday clinical practice, the most visible and dangerous manifestation of DPN is diabetic foot neuropathy:
- loss of protective sensation in the toes, forefoot and plantar surfaces
- change in foot biomechanics and balance, leading to falls
- increased risk of callus, ulceration and infection
- progression to Charcot arthropathy and possible amputation
Standard care focuses on:
- glycaemic control
- footwear and pressure off-loading
- regular podiatry
- education and self-inspection of the feet
- neuropathic pain medications where needed
These are all essential, but they are supportive rather than regenerative. They try to prevent further damage but do not actively repair nerves.
How PRP Might Help in the Diabetic Foot
Using ultrasound guidance, PRP can be injected perineurally around key lower-limb nerves relevant to foot sensation:
- tibial nerve and branches in the tarsal tunnel
- medial and lateral plantar nerves
- sural and saphenous nerves
- superficial peroneal nerve over the dorsum of the foot
The goal is not only to reduce burning pain, but to improve nerve function and protective sensation. If successful, this could:
- enhance awareness of pressure and trauma
- reduce the risk of new ulcers
- improve gait and balance
- support safer participation in exercise programmes
The trials discussed above (Hassanien, Anwar, Elsayed) primarily involved patients with neuropathic symptoms in the lower limbs, including the feet, and demonstrated improvements in both pain and nerve-conduction measures.
In parallel, separate literature shows PRP can improve healing of diabetic foot ulcers when applied to soft tissue wounds, further reinforcing the concept that PRP can beneficially modulate the diabetic foot micro-environment (although this is a distinct indication from neuropathy itself).
What a PRP-Based Neuropathy Pathway Looks Like in Practice
In a specialised regenerative clinic, a PRP neuropathy protocol typically includes:
- Comprehensive Assessment
- detailed history of neuropathic symptoms
- neurological examination (sensation, vibration, proprioception, reflexes)
- validated neuropathy scores (e.g. mTCNS, DN4)
- review of diabetes control and vascular status
- nerve-conduction studies where appropriate
- Imaging and Mapping
- ultrasound of the tibial, peroneal, sural and plantar nerves to identify swelling, entrapment or focal changes
- assessment of surrounding soft tissues and biomechanics (tendons, plantar fascia, intrinsic foot muscles)
- PRP Preparation
- autologous blood draw
- centrifugation using a standardised protocol (often leukocyte-reduced PRP for perineural use)
- strict aseptic technique
- Perineural Injection Technique
- ultrasound-guided placement of PRP around symptomatic nerve segments
- careful hydrodissection to free nerves from tight fascial planes where indicated
- often performed as a day-procedure under local anaesthesia
- Treatment Course
- commonly 2–3 sessions spaced 3–6 weeks apart, depending on severity and response
- reassessment of pain scores, sensory function and walking tolerance between sessions
- Integrated Rehabilitation
- ongoing optimisation of glycaemic control and cardiovascular risk factors
- gait retraining and strengthening of lower-limb musculature
- footwear and orthotic advice
- weight-bearing and activity plan tailored to the patient’s goals
This integrated approach treats neuropathy as a biological, biomechanical and functional problem, with PRP acting as the orthobiologic bridge between conservative management and more invasive interventions.
Safety Profile
Across neuropathy studies to date:
- PRP has been well tolerated, with no signal of serious treatment-related complications.
- The most common side-effects are transient: local discomfort, bruising, or temporary flare of symptoms.
- Because PRP is prepared from the patient’s own blood, there is no risk of immune rejection or drug–drug interaction; it does not interfere with diabetic medications.
Standard procedural risks (infection, bleeding, nerve irritation) still apply and must be minimised by proper technique, imaging guidance and patient selection.
Limitations and Unanswered Questions
Despite the encouraging data, several limitations must be acknowledged:
- Most DPN trials to date involve modest sample sizes and follow-up of 6–12 months.
- Protocols vary in PRP formulation, dose, frequency and injection sites, making it difficult to define a single “gold-standard” regimen.
- Long-term data on durability of benefit, need for maintenance injections, and cost-effectiveness are still emerging.
- PRP is not a substitute for good diabetes control; it should be viewed as an adjunctive therapy.
For these reasons, professional bodies have not yet formally endorsed PRP as a first-line, guideline-mandated treatment for DPN. Instead, it sits in the realm of advanced, evidence-informed regenerative care for selected patients.
My Clinical View
From a regenerative-medicine standpoint, the trajectory of evidence is clear:
- PRP has proven safety and efficacy in multiple peripheral neuropathies (especially carpal tunnel syndrome).
- Animal and mechanistic studies strongly support its role in nerve regeneration and inflammation control.
- Early but well-designed studies in diabetic peripheral neuropathy show consistent improvements in pain, clinical scores and nerve-conduction parameters compared with conventional therapy alone.
In my opinion, it is reasonable to view PRP as:
- A biologically rational, minimally invasive treatment that targets the micro-environment of damaged nerves.
- A bridge between symptomatic pharmacology and irreversible surgery, especially in patients with painful diabetic foot neuropathy who remain symptomatic despite best medical management.
- A candidate disease-modifying tool, particularly if combined with aggressive optimisation of metabolic control, footwear, biomechanics and rehabilitation.
We must remain honest that more large-scale, standardised trials are needed. But equally, it would be inaccurate to dismiss PRP as “experimental” in the colloquial sense. It is an emerging, orthobiologic option supported by growing clinical evidence and strong mechanistic plausibility, particularly for patients who have exhausted conventional approaches.
Take-Home Messages for Patients
- Diabetic neuropathy, especially in the feet, is common and can be disabling.
- Standard medications often only partially control pain and do not repair nerve damage.
- PRP is prepared from your own blood and aims to support nerve healing and reduce inflammation, not just mask symptoms.
- Clinical studies in diabetic neuropathy have shown meaningful improvements in pain, numbness and nerve function, with a good safety profile.
- PRP is best used as part of a comprehensive treatment plan, alongside careful diabetes management, foot care and rehabilitation.
If you have diabetic foot neuropathy and are interested in regenerative options, a detailed assessment can determine whether perineural PRP injections might be appropriate in your case.
References
Fresh PRP gel reduces sciatic nerve–associated neuropathic pain by suppressing TNF-α and IL-6 in rats. Cureus. 2025.
Hassanien M, et al. Perineural platelet-rich plasma injection in painful diabetic neuropathy: randomized controlled study. Pain Med. 2020.
Anwar S, et al. Effectiveness of platelet rich plasma treatment and its comparison with pregabalin in painful diabetic polyneuropathy: randomized controlled clinical trial. Anaesth Pain Intensive Care. 2024.
Elsayed AA, et al. Role of platelet rich plasma in management of diabetic peripheral neuropathy: randomized case-control study. J Ultrasound. 2025.
Kennedy PJ, et al. Clinical application of platelet-rich plasma in peripheral neuropathies: a systematic review. Regen Ther. 2025.
Anitua E, et al. Effectiveness of platelet derivatives in neuropathic pain: a systematic review. Rev Neurol (Paris). 2024.
Hong P, et al. Safety and efficacy of platelet-rich plasma in carpal tunnel syndrome: systematic review and meta-analysis. Front Pharmacol. 2022.
Wu Y-T, et al. Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: randomized, single-blind trial. Sci Rep. 2017.
Wang S, et al. Evaluation of platelet-rich plasma therapy for peripheral nerve regeneration: from mechanism to clinical application. Front Bioeng Biotechnol. 2022.
Wang SL, et al. Platelet-rich plasma promotes peripheral nerve regeneration in rabbit models. Neural Regen Res. 2022.
